NVS - Novartis AG

NYSE - NYSE Delayed Price. Currency in USD
92.37
-0.43 (-0.46%)
At close: 4:02PM EDT

92.37 0.00 (0.00%)
After hours: 4:17PM EDT

Stock chart is not supported by your current browser
Previous Close92.80
Open93.60
Bid92.10 x 1400
Ask93.81 x 2200
Day's Range92.36 - 93.65
52 Week Range64.78 - 93.65
Volume1,461,344
Avg. Volume2,615,112
Market Cap206.606B
Beta (3Y Monthly)0.54
PE Ratio (TTM)17.51
EPS (TTM)5.27
Earnings DateN/A
Forward Dividend & Yield2.83 (3.05%)
Ex-Dividend Date2019-03-04
1y Target Est99.50
Trade prices are not sourced from all markets
  • Novartis wins Gilenya reprieve as judge blocks generics, for now
    Reuters10 hours ago

    Novartis wins Gilenya reprieve as judge blocks generics, for now

    Novartis has won a U.S. federal court order preventing rival generic makers from selling versions of the Swiss drugmaker's top-selling multiple sclerosis medicine Gilenya in the United States, at least until a patent dispute is resolved. Novartis had asked for a preliminary injunction to halt generics makers including Dr. Reddy's Laboratories, Mylan Pharmaceuticals, Torrent Pharma and Aurobindo Pharma, among others, from making or selling a Gilenya copy in the United States until a final decision on a Novartis patent for the medicine.

  • Reutersyesterday

    UPDATE 1-Conatus Pharma to explore options as liver disease drug fails trial

    Conatus Pharmaceuticals Inc said on Monday it plans to explore options and implement a restructuring plan after its liver disease drug failed in a mid-stage trial. The drug was being developed to treat patients with nonalcoholic steatohepatitis (NASH), a fatty liver disease where fat accumulation and inflammation can lead to scarring, or fibrosis, that impairs liver function. Novartis AG in 2017 had exercised its option with Conatus to develop emricasan.

  • Benzinga2 days ago

    The 5 Most Expensive Drugs In US: What You Should Know

    The upward trajectory of prescription drug prices in the U.S. has drawn the ire of lawmakers. Prices of drugs are staggeringly high in the U.S. when compared to other developed countries such as Japan and in Europe. House lawmakers are discussing a plan that could work to curb high drug prices.

  • This would be the worst-case scenario for health stocks, according to UBS
    MarketWatch3 days ago

    This would be the worst-case scenario for health stocks, according to UBS

    Health-care reform is coming, UBS analysts say, and it could have severe consequences for health companies.

  • Novo Nordisk's Haemophilia A Drug Esperoct Gets EU Approval
    Zacks4 days ago

    Novo Nordisk's Haemophilia A Drug Esperoct Gets EU Approval

    Novo Nordisk's (NVO) Esperoct gets EU approval for the treatment of adolescents (less-than or equal-to 12 years of age) and adults with haemophilia A.

  • Reuters4 days ago

    UPDATE 1-U.S. group says Novartis MS drug price out of line with benefit

    A U.S. group that reviews the value of medicines issued a critical report on Novartis's new multiple sclerosis drug Mayzent, calling its $88,561 list price "far out of line" compared with its benefits for patients. The Boston-based Institute for Clinical and Economic Review (ICER), which has been reviewing Mayzent for months, recommended that Novartis lower the drug's price. Novartis disputed the findings.

  • From generic drugs to gummies: Boulder CBD company buys Novartis pharmaceutical plant in Broomfield for $18.8M
    American City Business Journals5 days ago

    From generic drugs to gummies: Boulder CBD company buys Novartis pharmaceutical plant in Broomfield for $18.8M

    A large pharmaceutical plant in Broomfield that for years produced generic drugs has been bought by a Boulder CBD company that’s looking to expand its ingredient-selling business to manufacturing mainstream products, like gummies, tablets and topicals. Mile High Labs purchased Novartis AG’s (NYSE: NVS) Sandoz plant in Broomfield, 2555 W. Midway Blvd., on Wednesday, June 19, for $18.8 million, company officials confirmed to Denver Business Journal.

  • NVS or NVO: Which Is the Better Value Stock Right Now?
    Zacks6 days ago

    NVS or NVO: Which Is the Better Value Stock Right Now?

    NVS vs. NVO: Which Stock Is the Better Value Option?

  • Reuters7 days ago

    Online pharmacy flags possible new impurity in blood pressure drug

    Online pharmacy Valisure reported that it found a new cancer-causing impurity in some versions of widely prescribed blood pressure medicine valsartan, but U.S. regulators said on Tuesday that the amount in the drugs was well below levels deemed to be potentially harmful. Connecticut-based Valisure informed the U.S. Food and Drug Administration in a citizen petition https://www.regulations.gov/document?D=FDA-2019-P-2869-0001 last week that it had found through its own testing an impurity called dimethylformamide (DMF) in some batches of the drug. Valisure analyzed valsartan from multiple manufacturers including Novartis AG and several generic manufacturers.

  • Jazz's (JAZZ) New Sleep Drug Sunosi Gets Schedule IV Status
    Zacks7 days ago

    Jazz's (JAZZ) New Sleep Drug Sunosi Gets Schedule IV Status

    Jazz Pharmaceuticals' (JAZZ) recently approved sleep drug, Sunosi, receives schedule IV designation under controlled substance list from the Drug Enforcement Agency.

  • Moody's7 days ago

    Alcon Inc. -- Moody's assigns Baa2 ratings to Alcon Inc.'s unsecured debt facilities

    Moody's Investors Service ("Moody's") has assigned a Baa2 rating to Alcon Inc.'s ("Alcon" or "the company") facilities. The loans are senior unsecured obligations of Alcon Inc..The proceeds from the above facilities were used alongside a $500 million 3-year senior unsecured term loan A, a $1.5 billion bridge-to-bond senior unsecured term loan and around $300 million equivalent local drawn lines to fund a $3,000 million payment to Novartis AG (A1 stable) and have a cash balance of approximately $500 million at closing of the spin-off from Novartis AG in April 2019.

  • Roche's Rozlytrek Gets Approval in Japan for Solid Tumors
    Zacks7 days ago

    Roche's Rozlytrek Gets Approval in Japan for Solid Tumors

    Roche's (RHHBY) oncology portfolio gets a boost with the approval of Rozlytrek for neurotrophic tyrosine receptor kinase fusion-positive, advanced recurrent solid tumors.

  • J&J's (JNJ) Tremfya Meets Goal in Psoriatic Arthritis Study
    Zacks8 days ago

    J&J's (JNJ) Tremfya Meets Goal in Psoriatic Arthritis Study

    J&J's (JNJ) Tremfya meets the primary endpoint in a late stage study that evaluated the efficacy and safety of the drug for treating patients with psoriatic arthritis.

  • Novartis (NVS) Announces Promising Data on Tasigna & Hyrimoz
    Zacks8 days ago

    Novartis (NVS) Announces Promising Data on Tasigna & Hyrimoz

    Novartis (NVS) announces positive data on CML drugs and biosimilar Hyrimoz.

  • Financial Times11 days ago

    Bluebird Bio prices gene therapy at nearly $1.8m

    Bluebird Bio plans to price a new gene therapy for people with an inherited blood disorder at almost $1.8m per patient, and will try to persuade European healthcare systems to shell out for it by promising to only seek full payment if it works. Healthcare systems will pay an initial instalment of €315,000 but will only pay more instalments if the treatment helps the patient avoid blood transfusions. The Boston-based biotech start-up’s drug is part of a class of new transformative therapies that need to be administered only once and apply to a small patient population.

  • Roche Reports Positive Data on Rituxan for Pemphigus Vulgaris
    Zacks12 days ago

    Roche Reports Positive Data on Rituxan for Pemphigus Vulgaris

    Roche (RHHBY) announces positive data on rheumatic diseases drug, Rituxan, for pemphigus vulgaris.

  • Top Analyst Reports for Visa, Netflix & Accenture
    Zacks12 days ago

    Top Analyst Reports for Visa, Netflix & Accenture

    Top Analyst Reports for Visa, Netflix & Accenture

  • Ligand Inks Oncology Drug Discovery Deal With PhoreMost
    Zacks12 days ago

    Ligand Inks Oncology Drug Discovery Deal With PhoreMost

    Ligand's (LGND) subsidiary Vernalis enters research agreement with privately-held PhoreMost to design compounds targeting an undisclosed novel oncology target.

  • Barrons.com12 days ago

    A Stock Fund Challenges the Definition of Growth. It’s Paying Off.

    Elisa Mazen, who co-manages the $1.6 billion ClearBridge International Growth fund, isn’t afraid to take a broad definition of growth to find the best opportunities.

  • Roche's Rituxan Gets Priority Review for Blood Disorder
    Zacks13 days ago

    Roche's Rituxan Gets Priority Review for Blood Disorder

    Roche (RHHBY) gets Priority Review status from the FDA for Rituxan in children with two rare blood vessel disorders.

  • Novartis Reports Data on Cosentyx for Psoriatic Arthritis
    Zacks13 days ago

    Novartis Reports Data on Cosentyx for Psoriatic Arthritis

    Novartis (NVS) announces new data on psoriatic arthritis drug, Cosentyx.

  • Stoke Therapeutics boosts IPO goal by 40 percent
    American City Business Journals14 days ago

    Stoke Therapeutics boosts IPO goal by 40 percent

    Stoke now hopes to raise $123 million when it launches on the Nasdaq market in the coming weeks, according to documents newly filed with the SEC. It originally had filed plans for an $86.25 million initial public offering last month. Stoke could be the fifth Massachusetts biotech to go public this year.

  • Dr. Reddy's Reports Positive Top-Line Data on Psoriasis Drug
    Zacks15 days ago

    Dr. Reddy's Reports Positive Top-Line Data on Psoriasis Drug

    Dr. Reddy's (RDY) reports positive top-line results from the phase IIb study on PPC-06 (formerly referred to as XP23829) in patients with moderate to severe plaque psoriasis.

  • Moody's15 days ago

    Curium Bidco S.a.r.l -- Moody's assigns B2 CFR to Curium Bidco S.a.r.l.; outlook stable

    Moody's Investors Service has today assigned a B2 corporate family rating (CFR) and a B2-PD probability of default rating (PDR) to radiopharmaceutical products provider Curium Bidco S.a.r.l.. Concurrently, Moody's has assigned B2 ratings to the proposed senior secured first lien term loans B maturing in 2026, split into a €485 million equivalent US dollar-denominated tranche and a €250 million Euro-denominated tranche. Moody's has also assigned a B2 rating to the proposed pari passu ranking €120 million revolving credit facility (RCF) maturing in 2025. Senior secured first lien facilities shall be co-borrowed by Curium Bidco S.a.r.l., Curium Netherlands B.V. and Curium US Holdings LLC. The outlook is stable.